[Retrograde intravenous perfusion as ultima ratio in potential amputation patients with peripheral arterial occlusive disease]. 1995

G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
Klinik für Innere Medizin III, Klinikums der Friedrich Schiller Universität Jena.

In 21 patients with critical ischemia and/or inflammation of the leg facing possible amputation, retrograde intravenous perfusion (RVP) was used to administer fibrinolytics, vasodilators and antibiotics. Amputation was avoided in 15 patients. In 4 patients, RVP was interrupted due to unsuitable veins for putting in cannulas. After introducing a 3-in-1-Block (Winnie) for analgesia, 7 courses of treatment at least were reached before unbearable pain became a reason for stopping therapy. RVP should, therefore, be considered as the last resort in the treatment of critical ischemia and/or inflammation of the leg of patients facing possible amputation.

UI MeSH Term Description Entries
D007511 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. Ischemias
D007866 Leg The inferior part of the lower extremity between the KNEE and the ANKLE. Legs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010478 Chemotherapy, Cancer, Regional Perfusion Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part. Cancer Chemotherapy, Regional Perfusion,Perfusion Cancer Chemotherapy, Regional,Regional Perfusion Antineoplastic Chemotherapy,Isolation Perfusion Cancer Chemotherapy,Regional Perfusion Cancer Chemotherapy
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin

Related Publications

G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
January 1991, VASA. Zeitschrift fur Gefasskrankheiten,
G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
January 1990, VASA. Zeitschrift fur Gefasskrankheiten,
G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
January 1972, Radiology,
G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
January 1992, VASA. Supplementum,
G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
January 1994, VASA. Zeitschrift fur Gefasskrankheiten,
G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
July 2022, BMC cardiovascular disorders,
G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
September 2013, European journal of radiology,
G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
January 1992, International angiology : a journal of the International Union of Angiology,
G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
August 2001, Clinical chemistry and laboratory medicine,
G Pöhlmann, and D Reinhardt, and G Grohmann, and G Eidner, and S Müller
April 1974, Angiology,
Copied contents to your clipboard!